GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-04-06| M&A

Ginkgo Bioworks Adds StrideBio’s AAV Platform To Step Up Gene Therapy Development

by Joy Lin
Share To

Ginkgo Bioworks has acquired StrideBio’s adeno-associated virus (AAV) capsid platform for an undisclosed sum to boost its AAV gene therapy development capabilities. The deal includes a transfer of several in-license agreements to Ginkgo, which will also be incorporated into its gene therapy platform. 

According to Ginkgo, the new assets will increase its offerings to target many different tissue types and potentially improve the safety profile of gene therapies. 

Along with the capsid discovery platform, Ginkgo will inherit StrideBio’s library of capsids, some of which have been tested in large animal models and have performed in terms of efficacy and selectivity. The more advanced candidates will be available for licensing and partnership opportunities, said Ginkgo. 

Additionally, Ginkgo will receive StrideBio’s lead preclinical candidate for arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare genetic heart disease. The company mentioned plans to sell or out-license the candidate to a potential partner. 

Related article: Ginkgo Bioworks and Merck’s Collaboration Worth Up to $144 million

StrideBio Strives to Overcome Current AAV Therapy Limitations

StrideBio’s platform, which it calls STRIVE, uses a structural engineering approach to generate AAV capsids that overcome the limitations of current AAV therapies. The company claims that their capsids come with the benefit of reduced seroprevalence (meaning the capsids are less likely to come under attack from the body’s immune system), improved tropism for cell types (e.g. in the nervous system or muscle), and increased gene transfer efficiency. 

“The StrideBio team has built a deep pipeline of AAV capsids and libraries to address critical challenges facing clinical gene therapy with a focus on reducing vector dose and improving safety by limiting off-target biodistribution,” said Aravind Asokan, Ph.D, who co-founded StrideBio with Pat Ritschel and the late Mavis Agbandje-McKenna.

“With Ginkgo’s expertise and scale, we hope to amplify this effort and deploy this platform to the gene therapy industry and ultimately, patients,” said Asokan.

Ginkgo Takes Steps To Expand Gene Therapies

In May 2021, Ginkgo signed a deal worth $120 million with Biogen to enhance the AAV production capabilities of Biogen’s gene therapy manufacturing processes. 

In January 2022, Ginkgo announced a collaboration with Selecta Biosciences to develop next-generation AAV capsids with improved transduction, tissue tropism, and reduced immunogenicity. Later that year, the company acquired Altar and Circularis, bringing in the former’s automated instruments and the latter’s circular RNA and screening platform to advance their gene therapies. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
$810 Million Turned Into a Rare Disease Revolution with Japan’s Nippon Shinyaku’s and USA’s REGENXBIO’s Partnership
2025-01-21
Ginkgo Job Cuts Expected to Affect at Least 35% of Workforce, Eliminating Over 400 Jobs
2024-07-02
Revolutionizing Treatment: ASGCT’s Clinical Trials Spotlight on Immunotherapy, Cancer Vaccines, and Auditory Diseases
2024-05-09
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top